Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX - Wikidata - wikimedia - TriplyDB

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

http://www.wikidata.org/entity/Q33739357

about

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect Integration strategy is a key step in network-based analysis and dramatically affects network topological properties and inferring outcomes.AKT regulates NPM dependent ARF localization and p53mut stability in tumors.Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013 Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays.The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications Therapeutic targets in triple negative breast cancer.p53 expression in breast cancer predicts tumors with low probability of non-sentinel nodes infiltration.New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Anticancer effects of liriodenine on the cell growth and apoptosis of human breast cancer MCF-7 cells through the upregulation of p53 expression Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function.

P2860

Q28085062-9D173958-D91C-42B7-8596-E16DEB50E5A4 Q28544712-D2C6B606-35F9-43E7-AA65-B06603B0794B Q34177262-6E46E328-78B3-4DD5-8044-743E988FDF5D Q34227622-31825E4D-11AB-46C5-819D-F898C4FB9A4F Q35813033-E4BB964B-0426-49EA-924F-CF39AE52CBDB Q36085418-7B983D0B-DFC1-4E4E-808B-4736C914CB79 Q36295039-2509D038-48AF-49D3-9FA7-C962BA5B578E Q36766027-D9E05E7E-2A5D-4706-A110-5B6D7FA1A740 Q37607746-61F10CBC-E959-4CE8-AE85-08922D371863 Q38084287-9FD8627F-3F21-49DB-89B8-B8239B0D598A Q38346114-D2B17ED2-1CEB-4499-B57B-F13ADE865D5C Q38417021-2E47265F-33F3-4D6C-B968-4E6DE52CD8BE Q39638185-93AD202C-6A6D-4CB4-9BD1-48B6D121F494 Q41144868-7BB5BF0D-4CEA-4E10-B53D-712B4B1D6C1C Q47291975-FCB1F712-2AA1-4600-97D7-56F4EDD084E6 Q49571721-51BCCE45-E31C-4DD9-9106-7AF2BEF0B9A9 Q53086894-E8667700-CDF1-491D-A36B-F184B66FC993 Q55421291-D02A77A7-0039-4BE3-9ACC-F908062C1A52

P2860

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

http://www.wikidata.org/entity/Q33739357

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@ast

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@en

type

label

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@ast

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@en

prefLabel

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@ast

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@en

P1433

Q33739357-6E90EE2C-1D39-4603-92F6-285771484F9B

P1476

Q33739357-A56B75D7-12D8-4888-AE1B-0F3A297E394A

P2093

Q33739357-0644E738-0178-447C-8947-10FD7683BD65

Q33739357-0BEC235C-9209-46A7-8D11-84F9FC808F31

Q33739357-1E5D1E57-A302-41FE-9D16-D75605E7DB43

Q33739357-1F6E4883-F580-4DBB-A4EA-F2AE3FBB3DAB

Q33739357-26CA616B-7768-4DA0-B4ED-D7AEFA9CA1E4

Q33739357-2E84117D-DBE7-4376-B90E-4133B0E83DF9

Q33739357-3D2D0CB2-745D-4CC4-9141-191F900E1778

Q33739357-406EE76F-8B49-46AB-A526-991E37B35411

Q33739357-9F2949ED-EDB4-4622-A9FF-CF1F1324CDE3

Q33739357-A6C3B4A1-EFBE-4A72-BF21-35E1B851297F

P2860

Q33739357-039FAE2F-E3C3-45F7-8A2B-7482AAEFEF67

Q33739357-0D0D55AC-49DE-43AC-A3B6-4E5E598C7E67

Q33739357-111A6566-5300-4923-BDA4-19FB93859B08

Q33739357-1173A86D-7FE2-4ED3-9A0D-A528C4CE08DE

Q33739357-136B0AE8-2E65-461E-9B1F-4006DF681266

Q33739357-1667B83E-DC17-406D-A88D-F43264C3C68F

Q33739357-17D363FE-E6F3-450E-85B3-5485FE89F967

Q33739357-2077700B-F76D-40C0-BD22-F25CC2B38BC4

Q33739357-23EC2CF4-A3FF-4CAA-9F3B-1DF2169CDE75

Q33739357-30392B9A-C866-4946-B2DF-DDAA7BFDB925

P2888

Q33739357-5F4C73E6-CA16-439F-8275-3E55184EF84D

P304

Q33739357-A3E37D15-D4CA-40F4-B1EE-2A78B7BCB5B3

P31

Q33739357-19084008-02C8-4D0F-AF41-B81C80990B8C

P356

Q33739357-4660EBF2-C7CD-4122-8DC1-5634634BB505

P433

Q33739357-7328AAF6-B0DE-45C8-AF51-79CEAFFA8CBC

P478

Q33739357-47C2D069-9A42-4FEE-B46C-5A4A86388A25

P50

Q33739357-3F44D335-6FB7-4765-8702-68FBD5ABC65B

P577

Q33739357-3EA11472-0443-4CB7-ABCC-8E968F91D387

P5875

Q33739357-A5BD90CB-275F-47F3-9BD7-555067B70A97

P6179

Q33739357-E7482155-799B-4B9A-AB16-F00FF9335328

P698

Q33739357-219C4A38-201E-43EE-8526-7B6656F55CB3

P932

Q33739357-923CF549-72A5-4F8D-92FC-89056C394346

P356

P1433

Breast Cancer Research

P1476

Prognostic interaction between ...... from IBCSG Trials VIII and IX

@en

P2093

Alan S Coates

http://www.w3.org/2001/XMLSchema#string

Aron Goldhirsch

http://www.w3.org/2001/XMLSchema#string

Barry Gusterson

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Musgrove

http://www.w3.org/2001/XMLSchema#string

Ewan K A Millar

http://www.w3.org/2001/XMLSchema#string

Meredith M Regan

http://www.w3.org/2001/XMLSchema#string

Monica Castiglione-Gertsch

http://www.w3.org/2001/XMLSchema#string

Richard D Gelber

http://www.w3.org/2001/XMLSchema#string

Robert L Sutherland

http://www.w3.org/2001/XMLSchema#string

Sandra A O'Toole

http://www.w3.org/2001/XMLSchema#string

P2860

p53 isoforms can regulate p53 transcriptional activity.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Gene expression patterns associated with p53 status in breast cancer.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

P2888

P304

R143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3348

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232929790

http://www.w3.org/2001/XMLSchema#string

P6179

1040097215

http://www.w3.org/2001/XMLSchema#string

P698

23127292

http://www.w3.org/2001/XMLSchema#string

P932

4053129

http://www.w3.org/2001/XMLSchema#string